61085-80-1 Usage
Description
4-Piperidinecarboxylic acid, 4-(phenylamino)-, methyl ester, also known as Methyl 4-(phenylamino)-4-piperidinecarboxylate, is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its ester functional group and its ability to form derivatives with potent biological activities.
Uses
Used in Pharmaceutical Industry:
4-Piperidinecarboxylic acid, 4-(phenylamino)-, methyl ester is used as an intermediate in the synthesis of Remifentanil Ester Hydrochloride (R143515), a controlled substance and an opioid analgesic. It plays a vital role in the development of potent pain relief medications.
Additionally, it is used as an intermediate in the synthesis of isothiocyanate derivatives of carfentanils and (methoxymethyl)fentanyls, which are opioid δ receptor irreversible inhibitors. These compounds have potential applications in the treatment of various conditions, including chronic pain and addiction management.
Check Digit Verification of cas no
The CAS Registry Mumber 61085-80-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,0,8 and 5 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 61085-80:
(7*6)+(6*1)+(5*0)+(4*8)+(3*5)+(2*8)+(1*0)=111
111 % 10 = 1
So 61085-80-1 is a valid CAS Registry Number.
61085-80-1Relevant articles and documents
Alternate Process for Remifentanil Preparation
-
Page/Page column 8, (2010/05/13)
An alternate process for synthesizing opiate or opioid analgesics and anesthetics, and intermediates thereof is provided. In particular, a process of synthesizing synthetic opiate or opioid compounds such as, for example, remifentanil, carfentanil, sufentanil, fentanyl, and alfentanil are disclosed.
N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
-
, (2008/06/13)
Novel N-aryl-N-(1-L-4-piperidinyl)arylacetamides useful as anti-arrhythmic agents, a method of treating arrhythmia which comprises the systemic administration of such compounds to warm-blooded animals and pharmaceutical compositions to be used therefor.
